Peritoneum carcinomatosis as a favourable prognostic factor for treatment with nanoliposomal irinotecan and fluorouracil plus leucovorin in advanced pancreatic cancer
A PS of 0, Alb >3.5 g/dL, CRP <0.5 mg/dL, CA 19-9 <1000 U/mL and the presence of peritoneal metastasis, especially without ascites, were favourable prognostic factors for survival in patients with advanced pancreatic cancer treated with nal-IRI + 5-FU/LV.
Authors
- Masahide Enomoto (ORCID: https://orcid.org/0000-0002-1854-9566)
- Taito Fukushima (ORCID: https://orcid.org/0000-0002-1345-5608)
- Kensuke Shiraishi
- Shin Maeda (ORCID: https://orcid.org/0000-0002-0246-1594)
- Naoto Yamamoto (ORCID: https://orcid.org/0000-0003-0613-5451)
- Masaaki Murakawa (ORCID: https://orcid.org/0000-0001-6140-7953)
- Satoshi Kobayashi (ORCID: https://orcid.org/0000-0002-2535-6586)
- Yuichiro Tozuka
- Junji Furuse (ORCID: https://orcid.org/0000-0003-0663-6117)
- Shun Tezuka (ORCID: https://orcid.org/0000-0003-2642-1658)
- Shotaro Tsunoda (ORCID: https://orcid.org/0000-0002-6366-2947)
- Rie Ohishi
- Tomomi Hamaguchi
- Makoto Ueno
Institutions
- Kanagawa Prefectural Hospital Organization (JP)
- Kanagawa Cancer Center
- Yokohama City University (JP)
Publication Details
- Journal
- Therapeutic Advances in Medical Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/17588359251351540
- Citations
- 1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05